RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
RHYTHM PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$88.23+2.06 (+2.39%)
Close on Oct 19, 2026
- Market cap
- $6.05B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$22.05 (−19.99%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
RHYTHM PHARMACEUTICALS, INC. grew revenue 53.5% to $239.92M over the twelve months to Jun 30, 2026. Free cash flow was -$116.63M.
Revenue
$239.92M
+53.5% vs. a year earlier
Operating income
-$200.63M
TTM Q2 2026
Free cash flow
-$116.63M
FY2025
EPS, diluted
-$3.11
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $6.05B
- P/E ratio
- –
- Price to sales
- 25.22
- Price to book
- 58.77
- Dividend yield
- –
- Free cash flow yield
- -1.93%
Fundamentals
- Revenue
- $239.92M
- Net income
- -$205.35M
- EPS, diluted
- -$3.11
- Free cash flow
- -$116.63M
- Book value per share
- $1.50
- Diluted shares
- 69M
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
$239.92M+53.5% YoY
Gross profit
$213.53M+53.1% YoY
Operating income
-$200.63M
Net income
-$205.35M
EPS, diluted
-$3.11
Free cash flow
–
Reported periodTrailing twelve months